Friday, 15 Feb 2019

You are here

Long-Term Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis

Only inhibitors of IL-1 (canakinumab) and IL-6 (tocilizumab) are FDA approved for use in children with systemic onset juvenile idiopathic arthritis (sJIA). Now, long-term data from the extension studies from two phase III studies shows that canakinumab yields long-term improvements with reduced glucocorticoid dosing with no new safety findings with long-term use. 

Nearly 80% of the 177 patients enrolled in the core study entered the open label extension, and of these, 75 patients (42%) completed the 5-year study.  The remaining 102 (58%) discontinued mainly for inefficacy. 

Discontinuation rates noted were higher in late responders (81%) compared with early responders (29%) to canakinumab.

At 2 years, aJIA-ACR 50/70/90 response rates were 62%, 61% and 54%, respectively.

Clinical remission was achieved by 20% of patients at month 6; 32% at 2 years. A JADAS low disease activity score was achieved by 49% of patients at 2 years.

A total of 128/177 (72.3%) patients were on glucocorticoids at entry and 15.6% discontinued and 22% tapered steroids to 0.150 mg/kg/day.

Overall the safety profile of canakinumab remained unchanged.  Serious adverse events included flares of sJIA (25 events or 5.24/100 patient-years) and 13 patients with macrophage activation syndrome (17 events or 3.56/100 patient-years) and there were no new deaths.

One limitation of this study may be the number of dropouts - with 58% of the patients discontinuing canakinumab over the 5 years. This may be explained by the very long duration of the LTE and the fact that some patients with sJIA will spontaneously remit. 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

No Added Benefit to MRI-Guided Therapy in Rheumatoid Arthritis

A treat-to-target (T2T) strategy to manage rheumatoid arthritis hinges on clinical metrics to optimize therapy. But investigators from Denmark have shown that using magnetic resonance imaging–guided T2T failed to improve disease activity remission rates or reduce radiographic progression.

Differing Effects of Smoking and HLA-DRB1 in Seropositive Rheumatoids

Analyses from the Swedish EIRA incident rheumatoid arthritis cohort study shows that smoking and HLA-DRB1 exert differential effects on serologically defined RA subsets - but that the strongest influence was seen in double positive (CCP+, RF+) individuals.

Update on Pregnancy Management in RA

Two recent reports offer good news to rheumatoid arthritis (RA) women who are planning to become pregnant. 

The first studies, RA women experiencing fertility issues who turn to assisted reproductive technology (ART) shows that live births were significantly lower in women with rheumatoid arthritis receiving ART treatment compared to usual rates in women without rheumatoid arthritis.

Multidisciplinary Recommendations for Rheumatoid Foot Problems

Approximately 90% of patients with rheumatoid arthritis (RA) have foot problems. A multidisciplinary panel (including 2 patients, 22 professionals (rheumatologists, rehabilitation physicians, orthopaedic surgeons, specialized nurses, podiatrists, orthopaedic shoe technicians, pedicurists, researchers) in the Netherlands set out to develop recommendations for those who treat RA foot problems. 

Does Seropositivity Change with Therapy?

A subanalysis of the early rheumatoid arthritis (RA) "IMPROVED" study has shown that changes in RA-autoantibody levels are not associated with disease activity or or long-term drug response, but instead reflect intensity of immunosuppression. Thus while autoantibody levels may be modifiable by our best therapies, modifying CCP or RF levels appears to have limited clinical relevance.